Market research
7RG1.F Regulus Therapeutics Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- 0.0%
- Beta
- 2.17
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- 0.0%
- Beta
- 2.17
About
About Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7RG1.F discussion.
5 years, 5 months ago
Regulus Therapeutics Inc is currently in a long term downtrend where the price is trading 32.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Regulus Therapeutics Inc's total revenue rose by 27677.8% to $5M since the same quarter in the previous year.
Its net income has increased by 73.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 163.3% to $3M since the same quarter in the previous year.
Based on the above factors, Regulus Therapeutics Inc gets an overall score of 4/5.